Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...

Select stocks may be just fine despite tariffs and the economic damage they could cause. The S&P 500 plummeted 4.8% Thursday ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...

A majority of U.S. Senators voted on Thursday to confirm Dr. Mehmet Oz, the celebrity physician nominated by President Donald ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...